ライフサイエンスコーパス: PLA2

1 ived leukocytes were Lp-PLA2-deficient (bmLp-PLA2 (-/-)).

2 A2alpha (cPLA2alpha) or calcium-independent PLA2.

3 five percent of participants had abnormal Lp-PLA2.

4 future challenge with a near-lethal dose of PLA2.

5 y response in part by effects elicited by Lp-PLA2.

6 3) complexes with a wide range of mutants of PLA2.

7 allosteric states of the interface activated PLA2.

8 ng of the sulfate head group in contact with PLA2.

9 s is characterized by local production of Lp-PLA2.

10 branes on the activation of human pancreatic PLA2.

11 inhibitors for group VIA calcium-independent PLA2.

12 d substantially long dissociation rates from PLA2.

13 (20-30 min post-P4) rely on group X secreted PLA2.

14 intracellular PLA2, the calcium-independent PLA2.

15 ciation and subsequent enzymatic reaction of PLA2.

16 responses are dependent on CD1a protein and PLA2.

17 na benthamiana via recombinant expression of PLA2.

18 apoB, only prava40 led to a reduction in Lp-PLA2 (-15%, p = 0.008) and atorva10 to a decrease in OxL

19 g/dL) below the cut-off value of circulating PLA2 (2.07 nM, equivalent to 290 ng/dL) present in serum

20 BI)-induced neuroinflammation via activating PLA2/5-LOX/LTB4 cascade using a partial frontal lobe res

21 nd improves outcomes after SBI by activating PLA2/5-LOX/LTB4 cascade.

22 spholipase A2/5-lipoxygenase/leukotriene-B4 (PLA2/5-LOX/LTB4) axis is an important inflammatory signa

23 k of coronary heart disease (CHD), making Lp-PLA2 a potential therapeutic target.

24 Lipoprotein-associated phospholipase A2 (Lp-PLA2), a member of the phospholipase A2 family of enzyme

25 rapy significantly decreased the level of Lp-PLA2, a vascular-specific, inflammatory enzyme that pred

26 ing that bee venom-derived phospholipase A2 (PLA2) activates T cells through generation of small neoa

27 monstrated that the P2X7 receptor can induce PLA2 activation and arachidonic acid mobilization.

28 of these factors to the complex kinetics of PLA2 activation are not well understood.

29 tes competitively inhibited the thrombin and PLA2 activities.

30 LA2G7 single-nucleotide polymorphisms and Lp-PLA2 activity (3 prospective, 2 case-control, 2 cross-se

31 PLA2 activity (MJ33 sensitive) in cell lysates following

32 /d was associated with a 20% reduction in Lp-PLA2 activity (P<0.001), whereas Lp-PLA2 rose 3.6% with

33 nd PI use were positively associated with Lp-PLA2 activity and mass after adjusting for age, race, se

34 Here, we used pressure modulation of the PLA2 activity and of the membrane's physical-chemical pr

35 rction volume, sPLA2 IIA protein expression, PLA2 activity and significantly restored phosphatidylcho

36 e to develop a versatile assay that monitors PLA2 activity based on interactions with natural phospho

37 High PLA2 activity can be induced by thermal perturbations of

38 Lp-PLA2 activity correlated with several CHD risk markers.

39 PLA2G7 variants associated with Lp-PLA2 activity could evaluate whether this relationship i

40 lly be used as nanosensors for monitoring of PLA2 activity in biological samples with minimal sample

41 s that the previously reported difference in PLA2 activity in CSF samples from healthy and AD individ

42 ma (iPLA2gamma) accounts for the majority of PLA2 activity in rabbit ventricular myocytes and is resp

43 The total PLA2 activity in sonicated platelets was diminished, and

44 PLA2 activity of recombinant phosphoPrdx6 was decreased

45 Adding Lp-PLA2 activity tertiles to the model improved the predict

46 e of exosomes, which transferred cytoplasmic PLA2 activity to neighboring CD1a-expressing cells.

47 ine the association of the following: (1) Lp-PLA2 activity versus cardiovascular biomarkers and risk

48 nts for the top versus bottom quartile of Lp-PLA2 activity were 1.61 (95% confidence interval, 1.31 t

49 ariants associated with modest effects on Lp-PLA2 activity were not associated with cardiovascular ri

50 phox) binds to phosphoPrdx6 and inhibits its PLA2 activity, an interaction that could function to ter

51 IIA) mRNA and protein expression, increased PLA2 activity, and loss of phosphatidylcholine after 1-h

52 ER stress, and NOXA, but not the increase in PLA2 activity, indicating that PLA2 is upstream of these

53 Unlike Lp-PLA2 activity, PLA2G7 variants associated with modest ef

54 tic effects of the lipid phase transition on PLA2 activity, the membrane insertion depth of PLA2 incr

55 f lysophosphatidylcholine, the product of Lp-PLA2 activity, was documented on the mineralization of v

56 9V) showed the strongest association with Lp-PLA2 activity, with VV subjects having 7.2% higher activ

57 tion, immunohistochemistry, and enzymatic Lp-PLA2 activity.

58 sk Score tertile had significantly higher Lp-PLA2 activity.

59 nance (MR) imaging contrast agent to monitor PLA2 activity.

60 of membrane insertion, plays a major role in PLA2 activity.

61 correlate with their selective inhibition of PLA2 activity.

62 Phospholipase A2 (PLA2) activity has been shown to be involved in the sper

63 lipoprotein-associated phospholipase A(2)(Lp-PLA2) activity is associated with increased risk of coro

64 psids and maintained their phospholipase A2 (PLA2) activity, as determined by native dot blot Western

65 patatin-like proteins have phospholipase A2 (PLA2) activity, recombinant TgPL1 purified from Escheric

66 sitively characterised for phospholipase A2 (PLA2) activity, suggesting their plausible involvement i

67 been developed to monitor phospholipase A2 (PLA2) activity.

68 The phospholipase A2 (PLA2)activity of phosphorylated peroxiredoxin 6 (Prdx6)

69 Lp-PLA2, also known as platelet-activating factor acetylhyd

70 tivity of Ca(2+)-dependent phospholipase A2 (PLA2), an inflammatory protein that (i) plays a role in

71 Serum levels of Lp-PLA2, an enzyme that hydrolyzes oxidized phospholipids t

72 tically inert stoichiometric complex between PLA2 and any bile salts in which it forms a stable compl

73 ehavior that is comparable to that of native PLA2 and DeltaPLA2 with a deleted 62-66 loop.

74 Therefore, PLA2 and ENPP6 activities may represent a key step in th

75 PLA2 and ENPP6 may act in concert to generate phosphocho

76 Lp-PLA2 decrease included higher baseline Lp-PLA2 and IL-6 levels, smaller increases in total cholest

77 This study has investigated whether Lp-PLA2 and its major enzymatic product, lysophosphatidylch

78 Both PLA2 and melittin, an activator of endogenous PLA2, indu

79 The Lp-PLA2 and OxLDL were reduced in statin-treated groups, bu

80 The strongest inhibitory activities toward PLA2 and TG were found in the hydrolysates obtained by h

81 we propose that 2 enzymes-phospholipase A2 (PLA2) and ectonucleotide pyrophophatase/phosphodiesteras

82 e investigated the role of phospholipase A2 (PLA2) and the effects of PLA2 products (polyunsaturated

83 A2, lysophosphatidylcholine (a product of Lp-PLA2), and C-reactive protein.

84 ost similar to mammalian calcium-independent PLA2, and additionally contains leucine-rich repeats and

85 whereas both iPLA2beta and group X secreted PLA2 are involved in P4-induced AR.

86 57-72 loop and the H(48)DNCY(52) segment of PLA2 are involved in transmitting the effect of the coop

87 Interestingly, candidate genes in pla1 and pla2 are themselves related by an older duplication.

88 lipoprotein-associated phospholipase A2 (Lp-PLA2) are associated with cardiovascular disease and dem

89 ues to build supporting the usefulness of Lp PLA2 as a predictor of coronary events in the general po

90 as determined by native dot blot Western and PLA2 assays, respectively.

91 ts, an elicitor-responsive phospholipase A2 (PLA2) at the plasma membrane generates signal molecules

92 Lp-PLA2 augments the inflammatory response after MI and ant

93 The five PLA2-bile salt complexes each result in a partly occlude

94 sight into the regulatory role that specific PLA2-bile salt interactions are likely to play in fat me

95 previous measurements of the equilibrium for PLA2 binding to lipid membranes, the average number of e

96 The results show that PLA2 binding to model biomembranes is not significantly

97 e by preferentially inducing the activity of PLA2 but not LPCAT in human and mouse SCD erythrocytes.

98 ivated protein kinase) and phospholipase A2 (PLA2), but its action is independent of phosphoinositide

99 when HDL was destabilized in the presence of PLA2 by the action of cholesteryl ester transfer protein

100 enhanced binding and activation of the bound PLA2 by the bile salt induced anionic charge in a zwitte

101 mplex of pig pancreatic IB phospholipase A2 (PLA2) can be considered a proxy for interface-activated

102 We evaluated the association between Lp-PLA2, cardiac allograft vasculopathy (CAV) assessed by 3

103 lts and to determine associations between Lp-PLA2, cardiometabolic risk factors, and subclinical athe

104 Phospholipases A2 (PLA2) catalyze the hydrolysis reaction of sn-2 fatty aci

105 ions of a biphasic dependence of the rate of PLA2 catalyzed hydrolysis of zwitterionic glycerophospho

106 that lipid enzymes such as phospholipase A2 (PLA2) contain allosteric activator sites for specific ph

107 her work is necessary to document whether Lp-PLA2 could be considered as a novel target in CAVD.

108 disulfide linkages of several cytotoxins and PLA2 could be solved, including more than 20 disulfide b

109 thermore, we showed that the IgE response to PLA2 could protect mice from future challenge with a nea

110 ic activity of membrane-associated bee venom PLA2, covering a pressure range up to 2 kbar.

111 The group IVA cytosolic isoform of PLA2 (cPLA2alpha) was activated upon S. pneumoniae infec

112 the inflammatory process: phospholipase A2 (PLA2), cyclooxygenase 2 (COX-2), thrombin, and transglut

113 aglandin synthesis through the activation of PLA2, cyclooxygenases (COX-1 and -2) and prostaglandins

114 As a specific inhibitor of Lp-PLA2, darapladib has been shown to be protective against

115 levels; factors associated with a larger Lp-PLA2 decrease included higher baseline Lp-PLA2 and IL-6

116 whose bone marrow-derived leukocytes were Lp-PLA2-deficient (bmLp-PLA2 (-/-)).

117 Phospholipase A2 (PLA2)-dependent pathways are important in the regulation

118 tivate the enzyme group-IB phospholipase A2 (PLA2) derived from the pancreas.

119 RECENT FINDINGS: The group 1B PLA2 digestion of phospholipids in the intestinal lumen

120 The 3D homology model of each PLA2 displays a binding pocket that specifically accommo

121 dltA S. aureus are equally resistant to gV/X PLA2 during phagocytosis and when exposed to the purifie

122 in the liposomal membrane were hydrolyzed by PLA2, encapsulated Gd was released into bulk solution, r

123 We hypothesized that Lp-PLA2 (encoded by the PLA2G7 gene) is expressed in CAVD a

124 ib is an oral, selective inhibitor of the Lp-PLA2 enzyme.

125 PLA2 enzymes are an important pharmacological target imp

126 s showing distinct roles of several of these PLA2 enzymes in inflammatory metabolic diseases such as

127 cific drugs that target one or more of these PLA2 enzymes may be novel strategies for treatment of th

128 their binding mode with two human cytosolic PLA2 enzymes: group IVA cPLA2 and group VIA iPLA2.

129 Phospholipase A2 (PLA2) enzymes act at the membrane-water interface to acc

130 Phospholipase A2 (PLA2) enzymes, which catalyze the hydrolysis of phosphol

131 dividuals originates from differences in the PLA2 expression level rather than from the enzyme activi

132 Each member of the PLA2 family of enzymes serves a distinct role in generat

133 PURPOSE OF REVIEW: The phospholipase A2 (PLA2) family of proteins includes lipolytic enzymes that

134 Pig pancreatic IB phospholipase A 2 (PLA2) forms three distinguishable premicellar E i (#) (

135 The rapid evolution of PLA2 gene number appears to be due to transposon invasio

136 in and evolution of PLA2 toxins by examining PLA2 gene number, organization, and expression in both n

137 Patient studies showed that injected PLA2 generates lysophospholipids within human skin in vi

138 been tested with the human Group V secreted PLA2 (GV sPLA2) and the human Group VIA calcium-independ

139 and the human Group VIA calcium-independent PLA2 (GVIA iPLA2).

140 The products of PLA2 had opposing effects on TRPM8.

141 Selective inhibition of Lp-PLA2 has been postulated to reduce necrotic core progres

142 Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherogene

143 Lipoprotein-associated phospholipase A2 (Lp-PLA2) hydrolyses oxidized low-density lipoproteins into

144 conducted to describe the distribution of Lp-PLA2 in a cohort of human immunodeficiency virus (HIV)-i

145 confirm or refute a contributory role for Lp-PLA2 in CHD.

146 have data emerged demonstrating a role of Lp-PLA2 in development of advanced coronary artery disease.

147 a (cPLA2alpha) is thought to be the dominant PLA2 in eosinophils; however, eosinophils also have secr

148 This study tested the role of Lp-PLA2 in healing after MI.

149 furthering our understanding of the role of PLA2 in health and disease and in detecting the pharmaco

150 e release of AA, we investigated the role of PLA2 in local and systemic disease during S. pneumoniae

151 A fragment screen was conducted against Lp-PLA2 in order to identify novel inhibitors.

152 Higher expression of Lp-PLA2 in stenotic aortic valves was confirmed by quantita

153 These results support the role for Lp-PLA2 in the mechanism of regional vascular inflammation

154 the catalytic activity of phospholipase A2 (PLA2) in both pure and complex biological fluids.

155 lipoprotein-associated phospholipase A2 (Lp-PLA2) in calcific aortic valve disease (CAVD).

156 PLA2, increased significantly after SCI, may play a key

157 A2 activity, the membrane insertion depth of PLA2 increases only modestly above Tm.

158 We found that bee venom PLA2 induced a T helper type 2 (Th2) cell-type response

159 LA2 and melittin, an activator of endogenous PLA2, induced spinal neuronal death in vitro, which was

160 en together, this study demonstrates that Lp-PLA2 inhibition can effectively prevent diabetes-mediate

161 definitive proof, of a potential role for Lp PLA2 inhibition in coronary heart disease prevention.

162 The findings suggest that PLA2 inhibition or CD1a blockade may have therapeutic po

163 Systemic Lp-PLA2 inhibition using SB-435495 at 10 mg/kg (i.p.) effec

164 Administration of Manoalide, a PLA2 inhibitor or Zileuton, a 5-LOX inhibitor with VPC r

165 Pretreatment with the PLA2 inhibitor, aristolochic acid, abrogated the increas

166 on the efficacy of darapladib, a specific Lp PLA2 inhibitor, show beneficial changes in plaque morpho

167 h was substantially reversed by mepacrine, a PLA2 inhibitor.

168 (i.c.v) with mepacrine [a phospholipase A2 (PLA2) inhibitor], ibuprofen [a nonselective COX inhibito

169 X in eicosanoid formation was examined using PLA2 inhibitors and murine tracheal epithelial cells wit

170 effects, or randomized trials of specific Lp-PLA2 inhibitors are needed to confirm or refute a contri

171 lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors may play a role in reducing progression

172 r cells by inhibition of calcium-independent PLA2 (iPLA2).

173 Group VIA PLA2 (iPLA2beta) has a GTSTG serine lipase consensus seq

174 Elevated Lp PLA2 is also associated with stroke and heart failure.

175 othesis that local coronary production of Lp-PLA2 is enhanced in patients with early coronary atheros

176 Lp PLA2 is gaining acceptance as a useful biomarker of chro

177 Lp-PLA2 is highly abnormal in HIV-infected patients and is

178 Together, these results demonstrated that Lp-PLA2 is highly expressed in CAVD, and it plays a role in

179 Lp-PLA2 is independently associated with progression of CAV

180 ular and biochemical nature of intracellular PLA2 is not well understood in plants.

181 The crystal structure of Lp PLA2 is now available and offers insight into the links

182 Here we examined how bee venom PLA2 is sensed by the innate immune system and induces a

183 e increase in PLA2 activity, indicating that PLA2 is upstream of these events.

184 Phospholipase A2 (PLA2) is a conserved component of venoms from multiple s

185 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel marker and participant in vascular infl

186 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a risk factor for coronary artery disease (CAD)

187 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an emerging biomarker of cardiovascular disease

188 In addition, phospholipase A2 (PLA2) is highly expressed in psoriatic lesions and is kn

189 elopment of inhibitors for phospholipase A2 (PLA2) is important in elucidating the enzymes implicatio

190 Lipoprotein-associated phospholipase A2 (Lp PLA2) is postulated to occupy a key position in the path

191 A phospholipase A2 (PLA2) is thought to be involved in the acyl-editing proc

192 hosphatidylcholine, the active product of Lp-PLA2, is associated with endothelial dysfunction.

193 reaction (AR), but the molecular identity of PLA2 isoforms has remained elusive.

194 scular regulators, but the phospholipase A2 (PLA2) isoforms supporting their production within the ca

195 SEPR, MRC-2, Antithrombin III, SAA, CRP, NPS-PLA2, LEAP-1, and LBP.

196 High Lp-PLA2 level was associated with increase in plaque volume

197 Lp-PLA2 level>236 ng/mL (higher tertile) identified a subgr

198 y significant predictors of a decrease in Lp-PLA2 level.

199 ion independently predicted the change in Lp-PLA2 level.

200 lipoprotein-associated phospholipase A2 (Lp-PLA2) level was seen in the statin group, compared with

201 Elevated Lp-PLA2 levels associate with increased risk of cardiovascu

202 Lp-PLA2 levels correlate with an increased risk of recurren

203 In response to MI, Lp-PLA2 levels markedly increased in the circulation.

204 The Lp-PLA2 levels positively correlated with age (r = 0.09), b

205 Elevated Lp-PLA2 levels predict CHD events in apparently healthy old

206 Arterial Lp-PLA2 levels were similar in patients and control subject

207 to greater decreases in sCD14, hsCRP, and Lp-PLA2 levels, compared with EFV/FTC/TDF.

208 in HIV-infected individuals by decreasing Lp-PLA2 levels.

209 re noted for changes in sCD14, hsCRP, and Lp-PLA2 levels.

210 Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels predict incident coronary heart disease (CH

211 red with the Poaceae vascular plants TE1 and PLA2/LHD2 mutants.

212 .19, P=0.012) compared with patients with Lp-PLA2< or =236 ng/mL.

213 n, incubating cells with the two products of PLA2 (lysophosphatidic acid and arachidonic acid) mimick

214 ery and coronary sinus for measurement of Lp-PLA2, lysophosphatidylcholine (a product of Lp-PLA2), an

215 -based treatment had significantly higher Lp-PLA2 mass and activity than those who were treatment-nai

216 intima-media thickness (cIMT) had higher Lp-PLA2 mass and activity.

217 CAC) scores >100 had significantly higher Lp-PLA2 mass than those with lower or nondetectable calcium

218 Mean Lp-PLA2 mass was 313 +/- 105 ng/mL and activity 173 +/- 49

219 lipoprotein-associated phospholipase A2 (Lp-PLA2) mass or activity is associated with an increased r

220 Lp-PLA2 may be a useful marker for risk of CAV and a therap

221 Thus, Lp-PLA2 may be a useful therapeutic target for patients wit

222 Indeed, Lp-PLA2 may be an important link between lipid homeostasis

223 Lp-PLA2 may be used as an additional and more vascular spec

224 notherapy, the therapeutic administration of PLA2-MB treatment to mice that already had established a

225 To identify unknown PLA2-mediated activities on the molecular components of

226 raction that could function to terminate the PLA2-mediated NOX2 activation signal.

227 ifferent mechanism from the Ca(2+)-dependent PLA2-mediated phospholipid hydrolysis.

228 lipoprotein-associated phospholipase A2 (Lp-PLA2), Mercodia oxidized LDL (OxLDL) with antibody 4E6,

229 he later, reparative phase, infarcts of bmLp-PLA2 (-/-) mice contained Ly-6C(low) macrophages with a

230 Accordingly, bmLp-PLA2 (-/-) mice developed smaller and less inflamed infa

231 Consequently, the hearts of bmLp-PLA2 (-/-) mice healed more efficiently, as determined b

232 Compared with wild-type controls, bmLp-PLA2 (-/-) mice subjected to MI had lower serum levels o

233 Cs required Prdx6-PLA2 We propose that Prdx6-PLA2 modulates NOX2 activation by generation of LPC that

234 Thus, Prdx6-PLA2 modulates NOX2 activation through generation of LPC

235 lly trapped vesicle is quite small, only two PLA2 molecules at the lowest enzyme concentration studie

236 rattlesnakes ( approximately 6 mya), while a PLA2 myotoxin gene retained in C. atrox was deleted from

237 Lp-PLA2 net production in the coronary circulation was high

238 is hence markedly affected by HHP, rendering PLA2, next to being a primary osmosensor, a good candida

239 spitting cobra) venom contains 15% secretory PLA2 of its dry weight.

240 ice that lack the phospholipase A2 activity (PLA2) of Prdx6; addition of either lysophosphatidylcholi

241 t of the other class; for example, C. roseus PLA2 only accommodates C. roseus alkaloids.

242 When PLA2 or melittin was microinjected into the normal spina

243 optimized NP showed selectivity for venomous PLA2 over abundant serum proteins, was not cytotoxic, an

244 fferent sperm subpopulations, using distinct PLA2 pathways to achieve AR.

245 dependence of the initial catalytic rate of PLA2 peaks around the lipid phase transition temperature

246 in establishing drug tolerance by regulating PLA2/PKCalpha activity and reactive oxygen species.

247 udy, we observed expression of a cytoplasmic PLA2 (PLA2G4D) in psoriatic mast cells but, unexpectedly

248 Intracellular phospholipase A2 (PLA2) plays an important role in regulating oxylipin bio

249 the proteolytic and lipolytic activities of PLA2 proceed through different mechanisms.

250 f phospholipase A2 (PLA2) and the effects of PLA2 products (polyunsaturated fatty acids and lysophosp

251 enge with S. pneumoniae As phospholipase A2 (PLA2) promotes the release of AA, we investigated the ro

252 mice that already had established allergy to PLA2 protects all subsequently challenged animals.

253 erized the protein and lipid products of the PLA2 reaction with HDL.

254 oform (pla2g4a), iPLA2 isoform (pla2g6), and PLA2-receptor (pla2r1) were present in all tissues of bo

255 studies, hydrolysis of HDL phospholipids by PLA2 reduced the particle size without changing its prot

256 Selective inhibition of Lp-PLA2 reduces development of necrotic cores and may resul

257 containing signaling molecules; for example, PLA2 regulates the generation of precursors for the bios

258 Among snakes, phospholipase A2 (PLA2)-related toxins have evolved in different lineages

259 mentation maps to a genomic region (pla1 and pla2, respectively) containing adjacent, apparently rece

260 erve as the messengers downstream of DGK and PLA2, respectively.

261 on in Lp-PLA2 activity (P<0.001), whereas Lp-PLA2 rose 3.6% with pravastatin 40 mg/d (P<0.001).

262 nges were SAA (serum amyloid protein A), NPS-PLA2 (secreted phospholipase A2), and CA6 (carbonic anhy

263 e (NMR) and other complementary results with PLA2 show that decylsulfate molecules in E 2 (#) and E 3

264 tophagy gene ATG5 Accordingly, inhibition of PLA2 significantly decreased lipid droplets, decreased o

265 Inhibition of PLA2 similarly abolished the cold responses of the major

266 containing 20% palmitic acid and PEG induced PLA2-specific IgA and increased Foxp3(+) Treg frequencie

267 ils; however, eosinophils also have secreted PLA2 (sPLA2) activity that has not been fully defined.

268 limit of detection (LOD) of human secretory PLA2 (sPLA2) in up to 1000-fold-diluted cerebrospinal fl

269 nd human studies suggest that both secretory PLA2 (sPLA2)-V and sPLA2-IIA (encoded, respectively, by

270 In contrast to conventional PLA2 subcutaneous immunotherapy, the therapeutic adminis

271 f these methods require the use of unnatural PLA2 substrates that may alter enzyme kinetics, and prob

272 reorganization of alpha-helical segments of PLA2 takes place at the lipid water interface.

273 in detecting the pharmacodynamic effects of PLA2-targeting drug candidates.

274 ic phospholipase A2 (GIVA cPLA2) is the only PLA2 that exhibits a marked preference for hydrolysis of

275 a previously unknown proteolytic activity of PLA2 that is specific to apoA-I and may contribute to th

276 olipase A2 (cPLA2 ), an important isoform of PLA2 that mediates the release of arachidonic acid, play

277 tially inhibit the other major intracellular PLA2, the calcium-independent PLA2.

278 Mice were challenged with a lethal dose of PLA2 to evaluate protection against anaphylaxis.

279 he micellar complex formed by the binding of PLA2 to preformed micelles.

280 as critically dependent on phospholipase A2 (PLA2) to mobilize lysophospholipids and free fatty acids

281 e traced the genomic origin and evolution of PLA2 toxins by examining PLA2 gene number, organization,

282 The number of Lp-PLA2 transcripts correlated with several indexes of tiss

283 d significantly only when extracellular gIIA PLA2 was also present before phagocytosis.

284 Lp-PLA2 was assessed in 341 (25% women, 52% white, 74% on h

285 ApoA-I proteolysis by PLA2 was Ca(2+)-independent, implicating a different mec

286 onmineralized aortic valves revealed that Lp-PLA2 was increased by 4.2-fold in mineralized aortic val

287 Lp-PLA2 was measured in plasma aliquots using an enzyme-lin

288 e generation of LPC by PMVECs required Prdx6-PLA2 We propose that Prdx6-PLA2 modulates NOX2 activatio

289 and neutralizing venomous phospholipase A2 (PLA2), we demonstrate that broad-spectrum neutralization

290 To test the functional importance of Lp-PLA2, we generated chimeric mice whose bone marrow-deriv

291 (lipoprotein-associated phospholipase A2 [Lp-PLA2]) were compared.

292 idly increased activity of phospholipase A2 (PLA2), which led to an increase in cytoplasmic calcium,

293 subsequent inactivation of phospholipase A2 (PLA2), whose metabolites are known to modulate ion chann

294 , suggesting specific and direct reaction of PLA2 with apoA-I.

295 ienced an ACS event, direct inhibition of Lp-PLA2 with darapladib added to optimal medical therapy an

296 ted that RcsPLA2alpha functions in vivo as a PLA2 with HFA specificity.

297 used to examine the association of serum Lp-PLA2 with incident CHD (myocardial infarction, angina, o

298 Incubation of PLA2 with lipid-free apoA-I produced similar protein fra

299 al structures of the complexes of pancreatic PLA2 with the naturally occurring bile salts: cholate, g

300 The amphipathic bile salts are bound to PLA2 with their polar hydroxyl and sulfate/carboxy group